DIVA Laboratories, Ltd.

NT$30.25As of Sun 8 Nov 2026, 12:00 UTC
TPEx:4153Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR (1.18%)
Div yield 6.61%
ROE 11.53%
Diagnostics & Research
Beta (5Y) 0.26
PE TTM 15.50
TSR TTM (13.21%)
Mkt cap NT$1.775B
ROIC 22.53%
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$29
(2.66%)
22.72%
Buy 7|9|1|6|4
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.41
0.44
0.49
0.48
1.02%
7.65%
17.55%
11.09%
RevenueNT$M
146.1
146.4
152.9
161.9
11.91%
11.31%
11.58%
15.83%
Peers (US$53.60M)
Cap (US$)
PE
69.08M
40.34x
28.26M
52.31x
Capital
TTM
5Y
10Y
Leveragex
5.576
0.160
0.144
EBIT/Intx
6.261
2.888
2.754
Own earn%
41.68
5.07
1.56
Sh yield%
23.07
47.09
49.95
Owners
Insiders/Inst%
9.55
79.53
Short interest%
4.20
SBC / revenue%
5.71
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
21
Op margin range%
24–28
$1 testx
—
Incr. ROIC%
1